Anti-malarial Drugs Market is Booming Across the Globe by Share, Size, Growth, Segments and Forecast 2021-2027
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is prevalent in tropical and subtropical regions, particularly in Africa, where it is responsible for a significant burden of morbidity and mortality.
Anti-malarial drugs are medications used to treat or prevent malaria, and they play a crucial role in controlling the disease. The global Anti-malarial Drugs Market has been growing steadily over the past few years due to increased efforts to combat the disease and the development of new drugs.
Market Size and Growth:
The global Anti-malarial Drugs Market size was valued at USD 471.7 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 5.2% from 2021 to 2028.
The increasing prevalence of malaria in developing countries and the emergence of drug-resistant strains of the parasite are some of the key factors driving market growth. In addition, the development of new drugs with improved efficacy and safety profiles is expected to further boost market growth.
Types of Anti-Malarial Drugs:
There are several types of anti-malarial drugs available in the market, and they can be classified into four categories: chloroquine and related compounds, artemisinin-based combination therapies (ACTs), quinoline derivatives, and other drugs.
Hurdles in automating pharmacovigilance are projected to hamper growth of the global Pharmacovigilance Market.
Chloroquine and related compounds were once widely used as a first-line treatment for malaria but have become less effective due to the emergence of drug-resistant strains of the parasite. However, they are still used in some areas where resistance is not yet a problem.
One of the things driving the Anti-malarial Drugs Market expansion is the rise in incidence of traveler's malaria. ACTs are currently the recommended first-line treatment for uncomplicated malaria. They consist of a combination of an artemisinin derivative and a partner drug that has a longer half-life. The artemisinin component rapidly reduces the number of parasites in the blood, while the partner drug eliminates the remaining parasites.

Comments
Post a Comment